Results 31 to 40 of about 98,417 (285)

Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation

Journal of Experimental & Clinical Cancer Research, 2012
Objectives To study the hypothesis that gemcitabine treatment augments the chemoresistance to gemcitabine by clusterin (sCLU) upregulation. Clusterin inhibition could augment the chemosensitivity of human pancreatic cancer cells by inhibition of ...
Tang Yong, Liu Fenghua, Zheng Chunning, Sun Shaochuan, Jiang Yingsheng   +4 more
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer [PDF]

, 2015
Various regimens including molecular targeted agents have been examined in patients with cisplatin (CDDP)-resistant urothelial cancer (UC). However, some studies have been stopped owing to the development of severe adverse events.
Matsuo, Tomohiro, Ohba, Kojiro, Mitsunari, Kensuke, Asai, Akihiro, Miyata, Yasuyoshi, Sakai, Hideki   +5 more
core   +1 more source

Current Oncological Treatment of Patients with Pancreatic Cancer in Germany: Results from a National Survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society [PDF]

, 2009
Background: No data have previously been available regarding the current treatment of patients with pancreatic cancer (PC) in German hospitals and medical practices.
Jauch, Karl-Walter, Thomas Seufferlein, Sargent, Mirja, Seufferlein, Thomas, Christiane J. Bruns, Bruns, Christiane J., Stefan Boeck, Mirja Sargent, Karl-Walter Jauch, Heinemann, Volker, Claus Schäfer, Volker Heinemann, Boeck, Stefan, Schäfer, Claus   +13 more
core   +1 more source

SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling

Bangladesh Journal of Pharmacology
Gemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu, Xiaoping Mei, Xueming Zhang, Neng Qian, Qingjiang Yu, Hongkun Zhou   +5 more
doaj   +1 more source

Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway. [PDF]

PLoS ONE, 2016
Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs.
Zhen-Hua Wu, Chen Lin, Ming-Ming Liu, Jian Zhang, Zhong-Hua Tao, Xi-Chun Hu   +5 more
doaj   +1 more source

Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study

BMC Cancer, 2020
Background Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer. Although UC has been considered a highly aggressive malignancy, no clinical studies have addressed the efficacy of chemotherapy for unresectable UC ...
Hiroshi Imaoka, Masafumi Ikeda, Kosuke Maehara, Kumiko Umemoto, Masato Ozaka, Satoshi Kobayashi, Takeshi Terashima, Hiroto Inoue, Chihiro Sakaguchi, Kunihiro Tsuji, Kazuhiko Shioji, Keiya Okamura, Yasuyuki Kawamoto, Rei Suzuki, Hirofumi Shirakawa, Hiroaki Nagano, Makoto Ueno, Chigusa Morizane, Junji Furuse   +18 more
doaj   +1 more source

Novel Gemcitabine-Re(I) Bisquinolinyl Complex Combinations and Formulations With Liquid Crystalline Nanoparticles for Pancreatic Cancer Photodynamic Therapy

Frontiers in Pharmacology, 2022
With less than 10% of 5-year survival rate, pancreatic ductal adenocarcinoma (PDAC) is known to be one of the most lethal types of cancer. Current literature supports that gemcitabine is the first-line treatment of PDAC.
Hui Shan Liew, Chun-Wai Mai, Chun-Wai Mai, Mohd Zulkefeli, Thiagarajan Madheswaran, Lik Voon Kiew, Lesley Jia Wei Pua, Ling Wei Hii, Ling Wei Hii, Wei Meng Lim, May Lee Low, May Lee Low   +11 more
doaj   +1 more source

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison

BMC Cancer, 2008
Background Recent meta-analyses have found a survival advantage with gemcitabine based combinations over single agent gemcitabine in patients with advanced pancreatic cancer.
Neoptolemos John P, Starling Naureen, Cunningham David, Ghaneh Paula, Sultana Asma, Smith Catrin   +5 more
doaj   +1 more source

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

, 2006
Background Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with
Castellano Daniel, Kleeff Jörg, Vermorken Jan, Albert Abad Esteve, Simon van Belle, CASTELLANO, D, STOGER, H, Esteve, Albert Abad, Jochen Raedle, HERZOG, P, DAVIDSON, N, OETTLE, H, Balcke, Peter, SCHEITHAUER, W, DOBROWOLSKI, F, TEMPIA-CALIERA, AA, Neville Davidson, Langrehr, Jan M., Herzog Peter, Scheithauer Werner, Friess Helmut, HOSSFELD, DK, KOVAR, A, Herbert Stöger, Adrien A Tempia-Caliera, Jan M Langrehr, Neyns Bart, Bart Neyns, Castellano, Daniel, Oettle Helmut, Herzog, Peter, BALCKE, P, Dittrich, Christian, KATZ, F, Katz Frieder, Robert Hawkins, Hawkins Robert, Raedle, Jochen, PIEDBOIS, P, LANGREHR, JM, Pascal Piedbois, Werner Scheithauer, Dobrowolski, Frank, NIEDERGETHMANN, M, Nippgen Johannes, Hawkins, Robert, Van Belle, Simon, Piedbois Pascal, Raedle Jochen, Andreas Kovar, RAEDLE, J, HAWKINS, R, Stöger Herbert, Peter Balcke, Davidson, Neville, Tempia-Caliera, Adrien A., DITTRICH, C, Christian Dittrich, Hossfeld Dieter K, Tempia-Caliera Adrien A, Helmut Oettle, NIPPGEN, J, Esteve Albert, ESTEVE, AA, Balcke Peter, Friess, Helmut, Katz, Frieder, Oettle, Helmut, Hossfeld, Dieter K., Dobrowolski Frank, Peter Herzog, Daniel Castellano, Kleeff, Jörg, Niedergethmann Marco, Marco Niedergethmann, Dieter K Hossfeld, Jan Vermorken, Scheithauer, Werner, KLEEFF, J, Helmut Friess, Nippgen, Johannes, NEYNS, B, Jörg Kleeff, Dittrich Christian, Langrehr Jan M, Davidson Neville, Stöger, Herbert, Frank Dobrowolski, Frieder Katz, Kovar, Andreas, Johannes Nippgen, van Belle Simon, Niedergethmann, Marco, Vermorken, Jan, Kovar Andreas, FRIESS, H, Piedbois, Pascal, Neyns, Bart, VERMORKEN, J   +98 more
core   +1 more source